

DAFTAR PUSTAKA

- Aarsland, D., L Marsh., and A Schrag. 2009. Neuropsychiatric symptoms in Parkinson's disease. *Movement Disorder* 24: 2175-2186.
- Adams, J.H. and DI Graham. 1994. *An introduction to Neuropathology* Second edition. New York: Churchill Livingstone
- Alcaro, A., R. Huber R., and J. Panksepp. 2007. Behavioral functions of the mesolimbic dopaminergic system: an affective neuroethological perspective. *Brain Res Rev.* 56(2); 283-321.
- American Psychological Association, 2020. <https://www.apa.org/topics/anxiety/>
- American Psychiatric Association. 2013. *Anxiety Disorder*. Fifth Edition. 188-231
- Amir, D. 2012. *Neurotransmitter: Faktor Penentu Kekuatan dan Kelemahan Seseorang*. Jakarta: Penerbit Bandung Sains & Teknologi.
- Andreadou, E., M. Anagnostouli., and V. Vasdekis. 2011. The impact of comorbidity and other clinical and sociodemographic factors on health-related quality of life in Greek patients with Parkinson's disease. *Aging Mental Health*;15:913–21.
- Ayano, G. 2016. Dopamine: Receptors, Function, Syntesis, Pathways, Locations and Mental Disorders: Review of Literatures. *Journal of Mental Disorders and Treatment*, vol 2, 120.
- Balleine, B.W. and J.P. O'Doherty. 2010. Human and rodent homologies in action control: corticostriatal determinants of goal-directed and habitual action. *Neuropsychopharmacology* 35; 48-69.
- Baik, J.H. 2013. Dopamine Signaling in reward-related behaviors. *Front Neural Circuits* 7: 1-16
- Bartels, A., and K. Leenders. 2009. Parkinson's disease: The syndrome, the pathogenesis and pathophysiology. *Cortex*, 45(8), pp.915-921.

- Beaulieu, J.M., S. Espinoza., and R. Gainetdinov. 2015. Dopamine receptors-IUPHAR review 13. *Br J Pharmacol* 172:1-23.
- Bedford, L., D. Hay., A. Devoy., S. Paine., and D.G Powe. 2008. Depletion of 26s proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. *J Neurosci* 28(33): 8189-98.
- Booij, J., J. de Jong., K. de Bruin., R. Knol., and M.M de Win. 2007. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double blind, placebo controlled crossover study in healthy control subjects. *J Nucl Med* 48 (5); 359-66.
- Bordelon, Y. and A. Keener. 2016. Parkinsonism. *Seminars in Neurology*, 36(04), ;330-334.
- Borgonovo, J., C. Allende-Castro., A. Laliena., N. Guerrero., and H. Silva. 2016. Change in neural circuitry associated with depression at pre-clinical, pre-motor and early motor phases of Parkinson's disease. *Parkinsonism related disorder*. 1-8.
- Braak, H., K. Del Tredici., U. Rub., R.A. de Vos., and E.N.J. Steur. 2003. Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol Aging* 24(2):197-211.
- Broen, M.P., N.E. Narayen., M.L. Kuijf., and N.N. Dissanayaka. 2016. Prevalence of anxiety in Parkinson's disease: a systematic review and metaanalysis. *Movement Disorder*. 31: 1125-1133
- Cacabelos, R. 2017. Parkinson's Disease: From Pathogenesis to Pharmacogenomics. *International Journal of Molecular Sciences* 18: 551
- Chen, J.J., and L. Marsh. 2014. Anxiety in Parkinson's disease: Identification and management. *The Adv Neurol Disord* 7: 52-59

- Christopher, G.G., W. Poewe., O. Rascol., C. Sampaio., and G.T. Stebbins. 2004. *Movement Disorder Society Task Force Report on the Hoehn and Yahr Staging Scale: Status and Recommendations. Movement Disorders* Vol. 19, No. 9 ; 1020-1028
- Chuqulin-Arista, F., T. Alvarez-Avellon., and M. Menendez-Gonzalez. 2020. Prevalence of depression and anxiety in Parkinson disease and impact on quality of life: a community based study in Spain. *J Geriatri Neurol.* 33(4):207-13
- Cutler, R.G., and H. Rodriguez. 2003. *Critical Reviews of Oxidative Stress and Aging: Advances in Basic Science, Diagnostics and Intervention Volume I.* Singapore: World Scientific Publishing
- Dan, R., F. Ruzicka., O. Bezdicek., E. Ruzicka., and J. Roth. 2017. Separate neural representations of depression, anxiety, and apathy in Parkinson's disease. *Sci.Rep.* 7, 1216
- Deister, C.A., M.A. Teagarden., C.J. Wilson., and C.A Paladini. 2009. An intrinsic neuronal oscillator underlies dopaminergic neuron bursting. *J Neuro-sci* 29(50); 15888-15897.
- De Maagd, G., and A. Philip. 2015. Parkinson's disease and its management part 1: Disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. *P & t*, vol 40 No. 8, p. 504 – 10.
- Di Giuda, D. 2012. Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 1231-FP-CIT SPECT study. *Eur J Nucl Med Mol Imaging* 39; 1937-1948.
- Dissanayaka, N.N., E. White., J.D. O'Sullivan., R. Marsh., and N.A Pachana. 2014. The clinical spectrum of anxiety in parkinson's disease. *Movement Disorder*, 29: 967-975.

- Druj, G., S. Carnicella., C. Carcenac., M. Favier., and A. Bertrand. 2014. Loss of Dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in parkinson's disease. *Mol Psychiatry* 9; 358-367.
- Durjadin, K. and V. Sgambato. 2020. Neuropsychiatric disorders in Parkinson's disease: what do we know about the role of dopaminergic and non-dopaminergic systems? . *Frontiers in Neuroscience*. 14:25.
- Edison, P., I. Ahmed., Z. Fan., R. Hinz., and G. Gelosa. 2013. Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia. *Neuropsychopharmacology*. 38(6):938-49.
- Elsworth, J.D., and R.H Roth. 2009. Dopamine. Elsevier; 539-547.
- Elbaz, A., F. Moisan., S. Kab., F. Mohamed., and M. Canonico. 2016. Parkinson disease male-to-female ratios increase with age: French nationwide study and metaanalysis. *Journal Neurology Neurosurgery Psychiatry* ;87:952- 957.
- Esmail, S.2018. The diagnosis and management of Parkinson's disease. *Sch J Appl Sci Res*, 1(9): 13-19.
- Factor, A. and J. Weiner. 2008. Parkinson's disease: Diagnosis and clinical management. Second edition. Cardinal feature of early Parkinson's disease;47-49.
- Factor, S., Steenland and D. Higgins. 2011. Postural instability/gait disturbance in Parkinson's disease has distinct subtypes: an exploratory analysis. *Journal Neurology Neurosurgery Psychiatry*;564-568.
- Fahn, S. and J. Jancovic. 2007. Parkinsonisme: Clinical Feature and Differential Diagnosis. Principles and Practice of Movement Disorders 1st edition.
- Floresco, SB., A.R. West., and B. Ash. 2003. Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. *Nat Neurosci* 6:968.

- Gao, C., S. Smith., and M. Lones. 2018. Objective assessment of bradykinesia in Parkinson's disease using evolutionary algorithms: clinical validation. *Translational Neurodegeneration* 7:18.
- Giguère, N., S. Burke Nanni., and L.E. Trudeau. 2018. On cell loss and selective vulnerability of neuronal populations in Parkinson's disease. *Front Neurol*.
- Grace, A.A., S.B. Floresco., Y. Goto., and D.J. Lodge. 2007. Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. *Trends Neurosci* 30:220–227.
- Grimes, D., M. Fitzpatrick., J. Gordon., J. Miyasaki., and E. Fon. 2019. Canadian guideline for Parkinson disease. *Canadian Medical Association Journal*, 191(36);E989-E1004.
- Halliday, G. and H. McCann. 2009. The progression of pathology in Parkinson's disease. *Annals of the New York Academy of Sciences*, 1184(1): 188-195.
- Hanna, K. and A. Cronin-Golomb. 2012. Impact of anxiety on quality of life in Parkinson's disease. *Parkinsons Dis*, 202:640-707
- Hauser, R.A. 2012. Parkinson disease clinical presentation. *Medscape reference* ; 1-13.
- Hawke, P.C., B. Brown., and S. Hammon. 2017. Anxiety and its features in Parkinson's disease. *SM J Neuro Neurosci*; 3(1): 1-5.
- Hirsch, E.C., P. Jenner., and S. Przedborski. 2013. Pathogenesis of Parkinson's Disease. *Movement Disorders* 28: 24-30.
- Hwang, O. 2013. Role of Oxidative Stress in Parkinson's Disease. *Experimental Neurobiology*, 22(1): 11.
- Jelinger, K. 2014. Neuropathology of Parkinson's Disease: Inflammation in Parkinson's Disease. *Scientific and Clinical Aspects*: 36-40.

- Kalia, L.V., J.M. Brotchie., and S.H. Fox. 2013. Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials. *Mov Disord* 28(2):131–44.
- Kano, O., K. Ikeda., D. Cridebring., T. Takazawa., and Y. Yoshii. 2011. *Neurobiology of Depression and Anxiety in Parkinson's Disease*. SAGE-hindawi Acces to Research Parkinson's Diasease; 1-5.
- Kehoe, W.A. 2017. Generalized anxiety disorder. ACSAP 2017 Book 2 Neurologic/ Psychiatric Care.
- Khedr, M.E., A.A. Abdelrahman., Y. Elserogy., F.A. Zaki., and A. Gamea. 2020. Depression and Anxiety among patients with Parkinson's disease: frequency, risk factors, and impact on quality of life. *The Egyptian Journal of Neurology, Psychiatry and Neurosurgery*. 56:116.
- Khoo, T.K., A.J. Yarnall., G.W. Duncan., S. Coleman., and J.T. O'Brien. 2013. The spectrum of nonmotor symptoms in early Parkinson disease. *Neurology* 80(3):276–81.
- Klein, M.O., D.S. Battagello., A.R. Cardos., D.N. Hauser., and J.C. Bittencourt. 2018. Dopamine: functions, signaling, and association with neurological disease. *Cellular and molecular neurobiology*.
- Kouli, A., K.M. Torsney., and W.L. Kuan. 2018. Parkinson's Disease: Etiology, Neuropathology, and Pathogenesis. In: Stoker TB, Greenland JC, editors. *Parkinson's Disease: Pathogenesis and Clinical Aspects* [Internet]. Brisbane (AU): Codon Publications; Chapter 1. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK536722/>
- Kummer, A., F. Cardoso., and L.A. Texeira. 2010. Generalized anxiety disorder and the Hamilton Anxiety Rating Scale in Parkinson's diasease. *Neuropsychiatric* 68; 495-501.

- Liu, C., L. Kershberg., and J. Wang. 2018. Dopamine secretion is mediated by sparse active zone-like release sites. *Cell* 172:706–718.
- Leentjens, A.E., K. Dujardin., and L. Marsh. 2008. Anxiety rating scales in parkinson's disease: critique and recommendations. *Mov Disord* 23; 2015-2025.
- Magrinelli, F., A. Picelli., P. Tocco., A. Federico., and L. Roncari. 2016. Pathophysiology of Motor Dysfunction in Parkinson' Disease as the Rationale for Drug Treatment and Rehabilitation. *Parkinson's Disease*; 1-18
- Maina, G., M. Mauri., and A. Rossi. 2016. Anxiety and depression. *Journal of Psychopathology*. 22: 236-250.
- Maio, R.D., P.J. Barrett., E.K. Hoffman., C.W. Barrett., and A. Zharikov. 2016. α - Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease. *Sci Transl Med* 8(342):342.
- Marinus, J., K. Zhu., C. Marras., D. Aarsland., and J. Hilten. 2018. Risk factors for non-motor symptoms in Parkinson's disease. *Lancet Neurology*; 4-8.
- Mark, M. H. 2010. *Parkinson's Disease Handbook: A Guide for Patients and Their Families*. New Jersey: American Parkinson Disease Association, Inc.
- Massato, A., N. Plotegher., D. Boassa., and L. Bubacco. 2019. Impaired dopamine metabolism in Parkinson's disease pathogenesis. *Molecular Neurodegeneration BMC*; 1-21
- Marsili, L., G. Rizzo., and C. Colosimo. 2018. Diagnostic Criteria for Parkinson's Disease: From James Parkinson to the Concept of Prodromal Disease. *Frontiers in Neurology*, 9.
- Massano, J. and K.P. Bhatia. 2012. Clinical approach to Parkinson's disease: features, diagnosis, and principles of management. *Cold Spring Harbor perspectives in medicine* (6): 10-15.
- Mathew, S.J., J.D. Coplan., and A.L. Mailiza. 2001. Neurobiological mechanisms of social anxiety disorder. *American Journal of Psychiatry* 158; 1558-1567.

- Miocinovic, S., S. Somayajula., S. Chitnis., and J.L. Vitek. 2013. History, Application and mechanism of deep brain stimulation. *JAMA Neurology* 70; 163.
- Miller, G.W., R.R. Gainetdinov., A.I. Levey., and M.G. Caron. 1999. Dopamine transporters and neuronal injury. *Trends Pharmacol Sci* 20:424–429.
- Mele, B., J.H. Leduc., E.E. Smith., T. Pringsheim., and Z. Ismail. 2018. Detecting anxiety in individuals with Parkinson disease. *American Academy of Neurology Journal*;1-9.
- Melis, M. and M. Pistis. 2012. Hub and switches: endocannabinoid signalling in midbrain dopamine neurons. *Philos Trans R Soc Lond B Biol Sci.* 367(1607); 3726-3285.
- Menon, B., R. Nayar., S. Kumar., S. Cherkil., and A. Venkatachalam. 2015. Parkinson's Disease, Depression, and Quality of life. *Indian Journal of Psychological Medicine.* Apr – Jun 2015, Vol 37 Issue 2 ; 144-149.
- Moon, H.E. and S.H. Paek. 2015. Mitochondrial dysfunction in Parkinson's disease. *Exp Neurobiol* 24(2):103–16.
- Moriyama, T.S., A.C. Felicio., M.H. Chagas., V.S. Tardelli., and H. Ferraz. 2011. Increased dopamine transporter density in parkinson's disease patients with social anxiety disorder. *J Neurol Sci* 310; 53-57.
- Morikawa, H. and C.A. Paladini. 2011. Dynamic regulation of midbrain dopamine neuron activity: intrinsic, synaptic, and plasticity mechanisms. *Neuroscience*: 95-111.
- Muzerengu, S., D. Contrafatto., and K. Chaudhuri. 2007. Non-motor symptoms: Identification and management. *Parkinsonism and Related Disorders* 13 : 450–456.
- Noyce, A.J., J.P. Bestwick., L. Silveira – Moriyama., C.H. Hawkes., and Giovannoni. 2012. Meta- analysis of early nonmotor features and risk factors for

- Parkinson Disease. American neurological association neurol, Vol. 72 No. 6, p. 893 – 901.
- Oktariza, Y., L. Amalia., S. Sobaryati., and M. Kurniawati. 2019 . Evaluasi Kualitas Hidup Pasien Parkinson Berdasarkan Terapi Berbasis Levodopa. *Indonesian Journal of Clinical Pharmacy*, 8(4), p.246.
- Pagano, G., N. Ferrara., D. Brooks., and N. Pavese. 2016. Age at onset and Parkinson disease phenotype. *American Academy of Neurology*;86(15):1400-1407.
- Picillo, M. 2017. Association between dopaminergic dysfunction and anxiety in de novo Parkinson's disease. *Parkinsonism Related Disorder*. 37; 106-110
- Pontone, G.M., N. Dissanayka., L. Apostolova., R.G. Brown., R. Dobkin., and K. Dujardin. 2019. Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of parkinson's disease. *Nature Partner Journals Parkinson's Disease* 5: 1-9
- Pringsheim. T., N. Jette., A. Frolkis., and T. Steeves. 2014. The Prevalence of Parkinson's Disease: A Systematic Review and Meta-analysis. *Movement Disorders*, Vol. 29, No. 13 : 1583-1590.
- Quelhas, R. and M. Costa. 2009. Anxiety, depression, and quality of life in Parkinson's disease. *J Neuropsychiatry Clin Neurosci* 21; 413-419
- Qamar, M.A., A. Sauerbier., M. Politis., H. Carr., and P. Loehrer. 2017. Presynaptic dopaminergic terminal imaging and non-motor symptoms assesment of Parkinson's disease: evidence for dopaminergic basis?. *Nature partner journals Parkinson's disease Foundation*:1-20
- Schapira, A., K. Chaudhuri., and P. Jenner. 2017. Non-motor features of Parkinson disease. *Neuroscience*, vol.18: 435-450.
- Schrag, A. and J. Schott. 2006. Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. *The Lancet Neurology*, 5(4): 355-363.

- Setyono, J., E. Noviani., and U. Gunarto. 2010. Hubungan antara merokok dengan penyakit Parkinson di RSUD Prof. DR. Margono Soekarjo Purwokerto. *Mandala Health*: 81 – 6.
- Sossi, V., R. Fernandez., R. Nandhagopal., M. Schulzer., and J. McKenzie. 2010, Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. *Movement Disorder*, 25; 2717-2723.
- Su, X., K.A. Maguire-Zeiss., R. Giuliano., L. Prifti., and K. Venkatesh. 2008. Synuclein activates microglia in a model of Parkinson's disease. *Neurobiol* 29(11):1690–701.
- Thaler, A., A. Mirelman., Y. Jacob., R. Helmich., and B. Nuenen. 2014. A voxel-based morphometry and diffusion tensor imaging analysis of asymptomatic Parkinson's disease-related G2019S LRRK2 mutation carriers. *Movement Disorder*, 29; 823-827
- Thompson, E. 2015. Hamilton rating scale for anxiety (HAM-A). *Occup Med* 65: 601
- Tysnes, O.B. and A. Storstein. 2017. Epidemiology of Parkinson's disease. *Journal of Neural Transmission*, 124(8), 901–905.
- Ullrich, C., R. Mlekusch., A. Kuschig., J. Marksteiner., and C. Humpel. 2010. Ubiquitin enzymes, ubiquitin and proteasome activity in blood mononuclear cells of MCI, Alzheimer and Parkinson patients. *Curr Alzheimer Res* 7(6):549–55
- Valente, E.M., A.R. Bentivoglio., P.H. Dixon., A. Ferraris., and T. Ialongo. 2001. Localization of a novel locus for autosomal recessive early-onset Parkinsonism, PARK6, on human chromosome 1p35-p36. *Am J Hum Genet* 68(4):895–900.
- Vriend, C., P.S. Boedhoe., S. Rutten., H.W. Berendse., and Y.D. Van der Werf. 2016. A smaller amygdala is associated with anxiety in Parkinson's disease. *J Neurol Neurosurg Psychiatry* 87; 493-500.

Walsh, K. and G. Bennet. 2000. Parkinson's disease and anxiety. *Postgrad Med J*: 89-93.

Wang, Q., Y. Liu., and J. Zhou. 2015. Neuroinflammation in Parkinson's disease and its potential as therapeutic target. *Translational Neurodegeneration*, 4(1).

Weintraub, D., A.B. Newberg., M.S. Cary., A.D. Siderowf., and P.J. Moberg. 2005. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in parkinson's disease. *J Nucl Med* 46; 227-232.

Williams-Gray, C.H., R. Wijeyekoon., A.J. Yarnall., R.A. Lawson., D.P. Breen. 2016. Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD). *Mov Disord* 31(7):995-1003.

Wise, R.A. 2009. Roles for nigrostriatal-not just mesocorticolimbic-dopamine in reward and addiction. *Trends Neurosci.* 32(10): 517-524.

Zarrindast, M.R. and F. Khakpai. 2015. The Modulatory role of dopamine in anxiety-like behavior. *Archives of Iranian Medicine* 18: 591-599.

Zhu, K., J.J. van hiltten., and J. Marinus. 2017. Onset and evolution of anxiety in Parkinson's disease. *Eur J Neurol.* 24: 404-11.

